What to Watch Thursday: Gilead, Microsoft and the Markets
This morning, futures are once again sinking due to the coronavirus.
Let’s go over the top stories Thursday, which include a look at the markets, Microsoft and Gilead.
First Up: the Markets
Yesterday saw the markets swing like a pendulum in later trading during the day. The Dow closed down a little over 100 points. The Nasdaq closed down 0.6% and the S&P 500 closed down 0.8%.
With the futures pointing to an open in the red, this puts us on pace for the worst week since the global financial crisis of 2008.
Let’s take a look at oil and gold.
Oil is in a freefall due to the unknowns around the coronavirus. As Edward Moya of OANDA put it, “Oil prices will remain very vulnerable here as the pandemic fears could deliver a greater shock to demand than what happened during the financial crisis. In 2008, WTI crude fell from the record high of $147.27 all the way down to the mid-$30s.”
Gold on the other hand, may see a moment in the sun as investors turn to safe haven assets.
Goldman Sachs boosted its forecast for gold to $1800 from $1600. “In the event that the virus effect spreads to Q2, we could see gold top $1,800/oz already on a 3-month basis,” it noted.
Gold is trading near a seven-year high due to fears around the coronavirus.
And Then There’s Microsoft
The company issued a coronavirus sales warning late Wednesday.
Microsoft said that it will fall short of previously issued fiscal third-quarter sales guidance. The company had been expecting sales guidance of between $10.75 billion and $11.15 billion for its “more personal computing” business segment. The segment includes Windows OEM and Surface.
Over the past year, Microsoft is up over 51%.
And, Finally, Gilead
The company, which is developing a drug to combat the coronavirus, said that it’s launching a Phase 3 study.
Gilead Sciences said remdesivir will be tested on around 1,000 patients with both moderate and severe symptoms of the respiratory-focused coronavirus.
The World Health Organization has said that Gilead’s drug may be the “only one drug right now that we think may have real efficacy” in treating the disease.
Catch up on the Latest Videos on TheStreet!
- Inside Wednesday's Wild Market Ride - What Led Stocks Lower in Late Trading
- The Future Lies in Bitcoin Says Shark Tank’s Robert Herjavec
- Microsoft Says it Won’t Meet Q3 Personal Computing Guidance Due to Coronavirus
- Stressed About the Selloff? How Investors Should Approach Their Portfolios
- Starbucks Is Now Serving Beyond Meat, Eh?
